SHENZHEN, China, March 31, 2026 /PRNewswire/ -- LifeTech Scientific Corporation ("LifeTech" or the "Company", together with its subsidiaries, the "Group"; stock code: 1302.HK), a leading medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its audited consolidated results for the year ended 31 December 2025 (the "Reporting Period").

   -- Steady Revenue GrowthThe Group recorded revenue of approximately 
      RMB1,369.8 million, representing a year-on-year increase of approximately 
      5.1% during the Reporting Period. The growth was primarily driven by 
      strong sales of stent grafts, which increased by approximately 19.9% 
      year-on-year. 
   -- Solid ProfitabilityGross profit of the Group amounted to approximately 
      RMB1,019.1 million during the Reporting Period, representing a 
      year-on-year growth of approximately 3.8%. The gross profit margin was 
      approximately 74.4%. Excluding certain non-recurring items[1], the net 
      profit of the Company reached approximately RMB353.4 million during the 
      Reporting Period, representing a significant increase of approximately 
      24.9% year-on-year. 
   -- Strong Cash Position:As at 31 December 2025, the Group's cash and cash 
      equivalents were approximately RMB719.3 million, representing an increase 
      of approximately 8.0% compared with 31 December 2024. 

Note [1]: Such non-recurring items include (i) the share-based payment expenses; (ii) the other gains and losses resulting from financial assets at fair value through profit or loss ("FVTPL"); and (iii) the changes in fair value of the financial liabilities at FVTPL related to the redeemable shares of Biotyx Medical (Shenzhen) Co., Ltd.

Domestic Market Maintains Steady Growth, Overseas Business Posts Considerable Growth

In 2025, the Group steadily advanced in a complex and ever-changing market environment, continuously consolidating its leading position in the domestic market while accelerating its expansion into international markets.

Driven by its dual core strategies of "Innovation" and "Internationalization", the Group focused on addressing unmet global clinical needs and leveraged its global sales network to enhance synergies across branding, patents, distribution channels, clinical registration, and global operations. Domestically, it further strengthened its market foundation through broader adoption of its innovative product portfolio. Internationally, it earned wider recognition, achieving sustained and considerable growth in overseas revenue.

The domestic market performed steadily, with sales increasing by approximately 1.7% year-on-year, accounting for about 71.1% of the Group's total revenue. Overseas sales of the Group grew by approximately 14.4% year-on-year, accounting for approximately 28.9% of the total revenue.

In particular, the European market recorded a strong growth of approximately 25.9%, becoming the Group's largest overseas market and contributing approximately 12.1% of the total revenue.

Core Business Demonstrates Resilience

The Group currently operates three main product lines, including the Structural Heart Diseases (SHD) business, the Peripheral Vascular Diseases (PVD) business and the Cardiac Pacing and Electrophysiology $(CPE)$ business.

The revenue of the Group was approximately RMB1,369.8 million during the Reporting Period, representing a year-on-year growth of approximately 5.1%. This increase was mainly due to the increase in revenue from the sales of stent grafts, which rose by approximately 19.9% year-on-year.

SHD Business

The Group has established a diversified product portfolio in the SHD business, mainly including Left Atrial Appendage (LAA) occluders and three generations of congenital heart diseases occluders, aiming to address various market demands through differentiated product strategies.

During the Reporting Period, the sales contributed by the SHD business were approximately RMB511.7 million, representing a year-on-year decrease of approximately 3.0%. Continuous technological innovation and product upgrades will further enrich the Group's SHD product portfolio and enhance its global sales layout.

PVD Business

The Group is striving to provide global patients with technology-leading systematic and comprehensive interventional medical devices solutions to treat peripheral vascular diseases. Products offered by the Group in the PVD business mainly included vena cava filters, thoracic aortic aneurysm stent grafts, abdominal aortic aneurysm stent grafts, Iliac artery bifurcation stent grafts, aortic stent graft system, aortic arch stent graft system and thoracoabdominal artery stent graft system.

During the Reporting Period, the sales contributed by the PVD business were approximately RMB844.6 million, representing a year-on-year growth of approximately 12.4%.

CPE Business

The Company is the first manufacturer in China that has a complete product portfolio of domestic implantable cardiac pacemakers with international-level technology and functions.

During the Reporting Period, the sales contributed by the CPE business were approximately RMB13.5 million.

Research and Development

The Group adheres to independent innovation, aiming to provide medical devices with outstanding clinical value for patients and physicians worldwide. In 2025, the Group continuously strengthened its innovation capabilities and accelerated the development of products to maintain its leading position in the industry.

During the Reporting Period, the R&D investment (including capitalized expenditure) of the Group amounted to approximately RMB329.0 million, accounting for about 24.0% of the total revenue, leading to the following key milestones:

   -- Thoracoabdominal Artery Stent Graft System (consists of the G-Branch$(TM)$ 
      Thoracoabdominal Aortic Stent Graft System, SilverFlow(TM) PV Peripheral 
      Vascular Stent Graft System, G-Branch(TM) AE Main Body Extension Stent 
      Graft System, G-Branch(TM) AAA Bifurcated Stent Graft System and 
      G-Branch(TM) IE Iliac Extension Stent Graft System), Aortic Stent Graft 
      System (consists of the Ankura(TM)  Pro Aortic Stent Graft System and 
      Longuette(TM) Aortic Branch Stent Graft System), Aortic Arch Stent Graft 
      System (consists of the Ankura(TM) Plus Aortic Arch Stent Graft System 
      and CSkirt(TM) Aortic Arch Branch Stent Graft System), Peripheral Balloon 
      Dilatation Catheter (Large diameter), Yoscop(TM) Multi-loop Snare System, 
      SteerEase(TM)-m Introducer and LAA Closure Delivery System have obtained 
      the National Medical Products Administration ("NMPA") certification; 
   -- Ankura(TM) IIc TAA Stent Graft System has obtained the CE MDR (Medical 
      Device Regulation) certification; 
   -- Iliac Bifurcation Device (consists of the G-iliac(TM) Pro Iliac 
      Bifurcation Stent Graft System and SilverFlow(TM) Pro Internal Iliac 
      Stent Graft System), Peripheral High Pressure Balloon Dilatation Catheter 
      and Yuranos(TM) Pro Abdominal Aortic Stent Graft System, etc. are pending 
      registration approval in China; 
   -- Aortic Stent Graft System (consists of the Ankura(TM) Pro Aortic Stent 
      Graft System and Longuette(TM) Aortic Branch Stent Graft System), 
      Fitaya(TM) Vena Cava Filter System, Futhrough(TM) Stent Graft Balloon 
      Catheter, Yuranos(TM) Abdominal Aortic Stent Graft System, G-iliac(TM) 
      Iliac Bifurcation Device, Thoracoabdominal Artery Stent Graft System 
      (consists of the G-Branch(TM) Thoracoabdominal Aortic Stent Graft System, 
      SilverFlow(TM) PV Peripheral Vascular Stent Graft System, G-Branch(TM) AE 
      Main Body Extension Stent Graft System, G-Branch(TM) AAA Bifurcated Stent 
      Graft System and G-Branch(TM) IE Iliac Extension Stent Graft System) and 
      Aortic Arch Stent Graft System (consists of the Ankura(TM) Plus Aortic 
      Arch Stent Graft System and CSkirt(TM) Aortic Arch Branch Stent Graft 
      System) are pending registration approval of CE certification; 
   -- CS(TM) Concave Supra-arch Branched Stent-Graft System, X-Clip(TM) Mitral 
      Valve Clip System, Surecham(TM) Aortic Arch Single Branch Stent Graft 
      System (consists of the Aortic Arch Stent Graft System and Aortic Branch 
      Stent Graft System) and Congenital Heart Defect Occluder are currently at 
      the stage of pre-registration clinical enrollment in China; 
   -- Cera(TM) PFO Occluder has completed pre-marketing clinical enrollment and 
      is currently under clinical follow-up in China; 
   -- IBS Titan(TM) Sirolimus-Eluting Iron Bioresorbable Peripheral Scaffold 
      System is currently at the stage of clinical enrollment in China and in 
      Europe, and its CE registration application has been submitted; 
   -- IBS(TM) Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System has 
      successfully completed the three-year follow-up of the phase II clinical 
      study and two-year follow-up of the phase III clinical study. Currently, 
      its CE and NMPA registration application have been submitted; and 
   -- Congenital Heart Defect Occluder had been admitted into NMPA Special 
      Examination and Approval Procedure for Innovative Medical Devices 
      (the"Procedure"). It is the 16th product of the Company having obtained 
      admission to the Procedure. 

Intellectual Property Rights

Intellectual property is an internal driving force to improve our core competitiveness in the medical device market. As at 31 December 2025, the Group had filed a total of 2,631 valid patent applications worldwide, of which 1,217 patents had been granted.

Strategic Collaboration to Enter Electrophysiology Market

(MORE TO FOLLOW) Dow Jones Newswires

March 31, 2026 12:40 ET (16:40 GMT)